MorphoSys AG — Board/Management Information 2004

Sep 3, 2004

News Details

Ad-hoc | 3 September 2004 16:35

MorphoSys Announces Change in Management Board

Ad-hoc-announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. ——————————————————————————– MorphoSys Announces Change in Management Board MorphoSys AG (Frankfurt: MOR; Prime Standard Segment) announced today the departure of Dr. Thomas von Rüden, Chief Scientific Officer, from the Company. The departure will take place with immediate effect. Until a successor is appointed, the Company will continue to be managed by the other two Board members, Dr. Simon Moroney, Chief Executive Officer, and Dave Lemus, Chief Financial Officer. Dr. Moroney will add Research and Development to his responsibilities, while Dave Lemus will add Technical Operations to his responsibilities. Simultaneously, MorphoSys announced two promotions within the Company at the Vice President and Director level. Dr. Marlies Sproll, presently Vice President of Research and Development, is promoted to Senior Vice President in the same capacity. Dr. Barbara Krebs, presently Director of Business Development, is promoted to Senior Director. end of ad-hoc-announcement (c)DGAP 03.09.2004 Issuer’s information/explanatory remarks concerning this ad-hoc-announcement: About MorphoSys: MorphoSys develops and applies innovative technologies for the production of synthetic antibodies, which accelerate drug discovery and target characterization. Founded in 1992, the Company’s proprietary Human Combinatorial Antibody Library (HuCALâ) technology is used by researchers worldwide for human antibody generation. The Company currently has licensing and research collaborations with Bayer (Berkeley, California/USA), Biogen Idec Inc. (Cambridge, Massachusetts/USA), Boehringer Ingelheim (Ingelheim, Germany), Bristol-Myers Squibb (Wilmington, Delaware/USA), Centocor Inc. (Malvern, Pennsylvania/USA), GPC Biotech AG (Munich/Germany), Hoffmann-La Roche AG (Basel/Switzerland), ImmunoGen Inc. (Cambridge, Massachusetts/USA), Novartis AG (Basel, Switzerland), Oridis Biomed GmbH (Graz/Austria), Pfizer Inc. (Delaware/USA), ProChon Biotech Ltd. (Rehovot/Israel), Schering AG (Berlin/Germany) and Xoma Ltd. (Berkeley, California/USA). For further information please visit the corporate website at: http://www.morphosys.com/ . Statements included in this press release which are not historical in nature are intended to be, and are hereby identified as, “forward-looking statements” for purposes of the safe harbour provided by Section 21E of the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words including “anticipates”, “believes”, “intends”, “estimates”, “expects” and similar expressions. The company cautions readers that forward-looking statements, including without limitation those relating to the company’s future operations and business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward-looking statements. Factors that may affect future operations and business prospects include, but are not limited to, clinical and scientific results and developments concerning corporate collaborations and the company’s proprietary rights and other factors described in the prospectus relating to the company’s recent public offering. ——————————————————————————– WKN: 663200; ISIN: DE0006632003; Index: Nemax 50 Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover, München und Stuttgart 031635 Sep 04